6-amino-5-oxo-hexanoic acid | 3131-85-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-amino-5-oxo-hexanoic acid
• 英文别名: 6-amino-5-oxohexanoic acid；6-Amino-5-oxo-hexansaeure
• CAS: 3131-85-9
• 化学式: C₆H₁₁NO₃
• mdl: MFCD19204572
• 分子量: 145.158
• InChiKey: WQPBAGVCYBGCCF-UHFFFAOYSA-N

物化性质

• 沸点：
  324.4±22.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-amino-5-oxo-hexanoic acid 、 5-methoxy-3-(methoxyacetyl)levulinic acid 在 盐酸 、 碘 作用下， 以 aq. phosphate buffer 、 水 为溶剂， 反应 24.0h， 以3%的产率得到
  参考文献：
  名称：

  Expanded combinatorial formation of porphyrin macrocycles in aqueous solution containing vesicles. A prebiotic model

  摘要：

  组合过程在生命起源中的作用相对来说仍未得到探索。在之前报道的四吡咯大环可能的前生物起源化学模型中，两个二元酸（取代基=甲基、乙酸）和两个氨基酮（取代基=乙基、丙酸）的串联组合反应产生了多达 538 个卟啉（在相应的卟啉原氧化后）。反应以 1 ：每个反应物池中疏水和亲水取代基的比例为 1 : 1，生成的卟啉以 ∼1 ：1 的比例在水溶液和磷脂酰胆碱囊膜之间分配。在这里，改变[2 × 2]反应中疏水和亲水取代基的比例会相应地改变所得卟啉的极性曲线（产率为 3.5-9.0%）。在有脂质囊泡存在的情况下，四种二元胺和四种氨基酮（带有亲水性或疏水性取代基）发生反应，然后进行光氧化，得到卟啉，产率为 8.7%。生成的卟啉以 1 ：磷脂酰胆碱囊泡和水溶液之间的分配比例为 1:1，这与之前在[2 × 2]反应中观察到的情况相同。从荧光量子产率（Φf ∼ 0.1）可以看出，水溶液部分和囊泡部分都具有光化学活性。虚拟库生成软件（PorphyrinViLiGe）显示，[4 × 4]反应可生成多达 131 464 种卟啉。理化性质（分配、光活性）对组合扩展的相对不敏感性可能是生物前功能性的一个宝贵但未被重视的属性。

  DOI：

  10.1039/c3nj41041b
• 作为产物：
  描述：

  5-oxo-6-phthalimido-hexanoic acid ethyl ester 在 盐酸 作用下， 生成 6-amino-5-oxo-hexanoic acid
  参考文献：
  名称：

  Lartillot,S.; Baron,C., Bulletin de la Societe Chimique de France, 1964, p. 783 - 786

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRROLO TRICYCLIQUES, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION À TITRE D'INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012101032A1

  公开（公告）日：2012-08-02

  The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的三环吡咯衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用途。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof
  申请人：Tang Feng

  公开号：US20100160318A1

  公开（公告）日：2010-06-24

  3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.

  公式（I）的3-吡咯[ b ]环己烯-2-二氢吲哚酮衍生物或其药用盐及其用途。用于制备上述化合物的公式（II）的中间体。生物测定表明，上述化合物及其药用盐可以调节蛋白激酶（PKs）的活性，抑制酪氨酸激酶（PTKs）的活性，并抑制多种类型的肿瘤细胞。
• TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Caldarelli Marina

  公开号：US20130296305A1

  公开（公告）日：2013-11-07

  The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的三环吡咯衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面有用。本发明还提供了制备这些化合物的方法，包括这些化合物的制药组合物以及利用这些化合物或含有它们的制药组合物治疗疾病的方法。
• Thiazole derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0928790A1

  公开（公告）日：1999-07-14

  Compounds of formula I as well as pharmaceutically usable salts and esters thereof, wherein R1, R2 and R3 have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. They can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumour metastasing, tumour growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure as well as infection caused by viruses, bacteria or fungi.

  式 I 的化合物及其药用盐和酯 及其药用盐和酯，其中 R1、R2 和 R3 具有权利要求 1 所述的意义，可抑制粘附蛋白与不同类型细胞表面的结合，并相应地影响细胞-细胞和细胞-基质之间的相互作用。它们可以药物制剂的形式用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、Paget 病、糖尿病视网膜病变、黄斑变性、血管介入后的再狭窄、牛皮癣、关节炎、纤维化、肾衰竭以及由病毒、细菌或真菌引起的感染。
• Probing the active site of rat porphobilinogen synthase using newly developed inhibitors
  作者：Nan Li、Xiusheng Chu、Xiaojun Liu、Ding Li

  DOI：10.1016/j.bioorg.2008.11.001

  日期：2009.2

  The structurally related tetrapyrrolic pigments are a group of natural products that participate in many of the fundamental biosynthetic and catabolic processes of living organisms. Porphobilinogen synthase catalyzes a rate-limiting step for the biosyntheses of tetrapyrrolic natural products. In the present study, a variety of new substrate analogs and reaction intermediate analogs were synthesized, which were used as probes for studying the active site of rat porphobilinogen synthase. The compounds 1, 3, 6, 9, 14, 16, and 28 were found to be competitive inhibitors of rat porphobilinogen synthase with inhibition constants ranging from 0.96 to 73.04 mM. Compounds 7, 10, 12, 13, 15, 17, 18, and 26 were found to be irreversible enzyme inhibitors. For irreversible inhibitors, loose-binding inhibitors were found to give stronger inactivation. The amino group and carboxyl group of the analogs were found to be important for their binding to the enzyme. This study increased our understanding of the active site of porphobilinogen synthase. (C) 2008 Elsevier Inc. All rights reserved.